FDA panel endorses Pfizer’s COVID-19 vaccine booster for people 65 and older, high-risk patients
[ad_1] A U.S. (*65*) and Drug Administration (FDA) advisory panel on Friday endorsed emergency approval for the Pfizer-BioNTech COVID-19 vaccine booster shot not less than six months following the second dose amongst people ages 65 and older and these at excessive danger of occupational publicity and extreme COVID-19. The vote was 18-0. The vote will…